Table 2.
Baseline characteristics of 144 patients with early-stage gastric MALT lymphoma, stratified by First line treatment.
| Characteristic | Pharmacotherapy n=39(%) | Radiotherapy n=56(%) | RT+PT n=49(%) | p-Value | |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 14 (35.9) | 21 (37.5) | 19 (38.8) | 0.962 | |
| Male | 25 (64.1) | 35 (62.5) | 30 (61.2) | ||
| Age (years) | |||||
| mean (SD) | 53 (12.3) | 54 (12.5) | 51(14.1) | 0.49 | |
| Year of diagnosis | |||||
| 1998-2007 | 14 (35.9) | 0 (0.0) | 3 (6.1) | <0.001* | |
| 2008-2017 | 15 (38.5) | 22 (39.3) | 30 (61.2) | ||
| 2018-2021 | 10 (25.6) | 34 (60.7) | 16 (32.7) | ||
| Ann Arbor stage | |||||
| I | 21 (53.8) | 43 (76.8) | 25 (51.0) | 0.012 | |
| II | 18 (46.2) | 13 (23.2) | 24 (49.0) | ||
| HP status | |||||
| Negative | 6 (15.4) | 14 (25.0) | 8 (16.3) | <0.001 | |
| Positive | 16 (41.0) | 41 (73.2) | 39 (79.6) | ||
| Unknow | 17 (43.6) | 1 (1.8) | 2 (4.1) | ||
| Anti-HP therapy | |||||
| No | 27 (69.2) | 13 (23.2) | 10 (20.4) | <0.001 | |
| Yes | 12 (30.8) | 43 (76.8) | 39 (79.6) | ||
| MALT-IPI | |||||
| 0 | 29 (74.4) | 49 (87.5) | 44 (89.8) | 0.103 | |
| 1 | 10 (25.6) | 7 (12.5) | 5 (10.2) | ||
| LDH > UNL | |||||
| No | 33 (84.6) | 55 (98.2) | 48 (98.0) | 0.008* | |
| Yes | 6 (15.4) | 1 (1.8) | 1 (2.0) | ||
| Primary lesion | |||||
| Multiple | 17 (43.6) | 11 (19.6) | 18 (36.7) | 0.033 | |
| Single | 22 (56.4) | 45 (80.4) | 31 (63.3) | ||
| Ki67% | |||||
| ≤10 | 19 (48.7) | 43 (76.8) | 37 (75.5) | <0.001 | |
| 11~60 | 4 (10.3) | 7 (12.5) | 9 (18.4) | ||
| Unknow | 16 (41.0) | 6 (10.7) | 3 (6.1) | ||
| Ectopic chromosome | |||||
| No | 5 (12.8) | 19 (33.9) | 12 (24.5) | 0.071 | |
| Unknow | 26 (66.7) | 21 (37.5) | 25 (51.0) | ||
| Yes | 8 (20.5) | 16 (28.6) | 12 (24.5) | ||
| CD20+ | |||||
| Negative | 9 (23.1) | 4 (7.1) | 5 (10.2) | 0.028 | |
| Positive | 17 (43.6) | 32 (57.1) | 35 (71.4) | ||
| Unknow | 13 (33.3) | 20 (35.7) | 9 (18.4) | ||
| Radiotherapy dose | |||||
| 30-35Gy | 0 (0.0) | 49 (87.5) | 34 (69.4) | <0.001 | |
| 30Gy | 0 (0.0) | 1 (1.8) | 5 (10.2) | ||
| 36-42Gy | 0 (0.0) | 4 (7.1) | 10 (20.4) | ||
| No | 39 (100.0) | 2 (3.6) | 0 (0.0) | ||
| Disease progression | |||||
| Distant | 8 (20.5) | 1 (1.8) | 0 (0.0) | <0.001* | |
| Local | 5 (12.8) | 3 (5.4) | 1 (2.0) | ||
| No | 26 (66.7) | 52 (92.9) | 48 (98.0) | ||
| Final outcome | |||||
| Alive | 32 (82.1) | 56 (100.0) | 48 (98.0) | <0.001* | |
| Death | 7 (17.9) | 0 (0.0) | 1 (2.0) | ||
| Overall survival(months) | |||||
| Median | 76 | 40 | 62 | 0.015 | |
| IQR | 35-133 | 24-73 | 40-97 | ||
| *Fisher's exact test;MALT-IPI = MALT lymphoma prognostic index; | |||||
LDH, Lactate dehydrogenase; UNL, Upper normal limit; LNL, Lower normal limit;